Press Releases

LAVAL, QC and SEATTLE, Sept. 23, 2019 /PRNewswire/ - Today, our merged affiliates, NEOMED-LABS, Pacific Biomarkers and PAIRimmune, are proud to announce the launch of our new international name, Nexelis, along with our unified vision and capabilities.

NEW YORK and CAESAREA, Israel, Sept. 23, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"), a leading, global digital therapeutics company, today announced that Erez Raphael

BOSTON, Sept. 23, 2019 /PRNewswire/ -- Sagentia, the global product development and technology consultancy and a Science Group company, announces the launch of MediTheatre, its Virtual Reality 'showroom'. Delegates at The MedTech Conference in Boston on September 23rd-25th, will be the first to in

ROME, Sept. 23, 2019 /PRNewswire/ -- Promising results from the preclinical study conducted by Menarini Ricerche on MEN1611, a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development for the treatment of breast cancer. The poster entitled "Characterization of the mechanism of action and efficacy of MEN1611, a novel

BOSTON, Sept. 23, 2019 /PRNewswire/ -- FogPharma today announced the appointment of Fang Wang, Ph.D., as Vice President of Biology and Nancy Wilker, Ph.D., J.D., as Vice

SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced positive topline results from the "STAR Study", a Phase 2 dose-ranging study of tolperisone in acute muscle spasms of the back. The primary objective of the study was to assess the efficacy of

TUCSON, Ariz., Sept. 23, 2019 /PRNewswire/ -- UAVenture Capital, a Tucson-based venture capital fund dedicated to the commercialization of discovery products, technology and services emerging from the University of Arizona, today announced its third and fourth investments for Fund II, its eighth and ninth

HONOLULU, Sept. 23, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing CHASE (Cardiovascular Health Astaxanthin Supplement Evaluation) clinical trial. The CHASE clinical trial is a double-blind, randomized, placebo-controlled clinical trial evaluating the e

SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst event on Friday, October 4, 2019 from 8:00 a.m. to 11:30 a.m. ET in New York City, entitled "A New Chapter in PI3Kδ

MENLO PARK, Calif., Sept. 23, 2019 /PRNewswire/ -- Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today the appointment of Francesco Galimi, M.D., Ph.D., as Senior Vice President and Chief Medical Officer.